The Alteration and Clinical Significance of Th22/Th17/Th1 Cells in Patients with Chronic Myeloid Leukemia

Figure 3

Concentrations of IL-22, IL-17, and IFN-γ in PB or BM plasma of CML patients and healthy controls. (a) Concentrations of IL-22 in PB plasma from CP () patients were increased compared to in controls. No significant difference was found between ND and CP patients () or controls (). (b) Concentrations of IL-22 in BM plasma from ND patients, CP patients, and healthy controls. No significant difference was found between ND () or CP () patients and healthy controls. (c) Concentrations of IL-17 in PB plasma from ND patients, CP patients, and healthy controls. The concentrations of PB plasma IL-17 in ND () or CP () patients were significantly higher than in healthy controls. There was no significant difference between ND and CP patients (). (d) Concentrations of IL-17 in BM plasma from ND patients, CP patients, and healthy controls. There was no significant difference between ND () or CP () patients and healthy controls. (e) Concentrations of IFN-γ in PB plasma from ND patients, CP patients, and healthy controls. No significant difference was found between ND () or CP () patients and healthy controls. (f) Concentrations of IFN-γ in BM plasma from ND patients, CP patients, and healthy controls. The concentration of BM plasma IFN-γ in ND patients () was significantly higher than in healthy controls. There was no significant difference between ND and CP () patients.

(a)

(b)

(c)

(d)

(e)

(f)